BioCryst Pharmaceuticals' (BCRX) "Outperform" Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada reiterated their outperform rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX - Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. Royal Bank of Canada currently has a $10.00 price objective on the biotechnology company's stock.

Several other equities analysts have also recently weighed in on the company. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. StockNews.com raised BioCryst Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Tuesday, August 6th. JMP Securities increased their price objective on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a "market outperform" rating in a report on Tuesday, August 6th. Barclays raised their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an "equal weight" rating in a report on Tuesday. Finally, Needham & Company LLC reissued a "buy" rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $14.67.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX traded down $0.30 during mid-day trading on Tuesday, reaching $7.05. 4,070,731 shares of the company traded hands, compared to its average volume of 2,979,466. The stock has a market cap of $1.46 billion, a PE ratio of -11.87 and a beta of 1.89. The company's fifty day moving average is $7.84 and its two-hundred day moving average is $6.95. BioCryst Pharmaceuticals has a fifty-two week low of $4.03 and a fifty-two week high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.07). The company had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. BioCryst Pharmaceuticals's quarterly revenue was up 35.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.19) EPS. Research analysts forecast that BioCryst Pharmaceuticals will post -0.37 earnings per share for the current year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of BioCryst Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company's stock valued at $57,000 after buying an additional 1,322 shares during the last quarter. Xponance Inc. lifted its position in BioCryst Pharmaceuticals by 13.1% during the second quarter. Xponance Inc. now owns 12,980 shares of the biotechnology company's stock valued at $80,000 after purchasing an additional 1,505 shares during the period. Creative Planning raised its position in shares of BioCryst Pharmaceuticals by 5.9% in the third quarter. Creative Planning now owns 49,347 shares of the biotechnology company's stock worth $375,000 after acquiring an additional 2,734 shares during the period. CWM LLC raised its position in shares of BioCryst Pharmaceuticals by 200.0% in the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 3,772 shares during the period. Finally, Diversified Trust Co raised its position in shares of BioCryst Pharmaceuticals by 18.0% during the 2nd quarter. Diversified Trust Co now owns 24,752 shares of the biotechnology company's stock worth $153,000 after purchasing an additional 3,774 shares during the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.